LIDOCAINE HYDROCHLORIDE- lidocaine hydrochloride  injection Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

lidocaine hydrochloride- lidocaine hydrochloride injection

international medication systems, limited - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hydrochloride anhydrous 20 mg in 1 ml - lidocaine hydrochloride injection, usp is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed. lidocaine hcl is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.

NADOLOL tablet Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

nadolol tablet

mylan institutional inc. - nadolol (unii: fen504330v) (nadolol - unii:fen504330v) - nadolol 20 mg - nadolol tablets are indicated for the long-term management of patients with angina pectoris. nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with nadolol tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure educati

ATENOLOL tablet Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

atenolol tablet

mylan institutional inc. - atenolol (unii: 50vv3vw0ti) (atenolol - unii:50vv3vw0ti) - atenolol 25 mg - atenolol tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmhg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). these considerations may guide selection of therapy. atenolol tablets may be administered with other antihypertensive agents. atenolol tablets are indicated for the long-term management of patients with angina pectoris. atenolol tablets are indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. treatment can be initiated as soon as the patient’s clinical condition allows. (see dosage and administration, contraindications, and warnings.) in general, there is no basis for treating patients like those who were excluded from the isis-1 trial (blood pressure less than 100 mm hg systolic, heart rate less than 50 bpm) or have other reasons to avoid beta blockade. as noted above, some subgroups (e.g., elderly patients with systolic blood pressure below 120 mm hg) seemed less likely to benefit. atenolol tablets are contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure. (see warnings.) atenolol tablets are contraindicated in those patients with a history of hypersensitivity to the atenolol or any of the drug product’s components.

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE tablet Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

spironolactone and hydrochlorothiazide tablet

mylan institutional inc. - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - spironolactone 25 mg - spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see precautions section). spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. unnecessary use of this drug should be avoided. spironolactone and hydrochlorothiazide tablets are indicated for: edematous conditions for patients with: congestive heart failure: - for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; - the treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; - the treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: - aldosterone levels may be exceptionally high in this cond

POST PEEL PROTECTANT VITALITY INSTITUTE- hydrocortisone cream Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

post peel protectant vitality institute- hydrocortisone cream

vitality institute medical products - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 7.5 g in 100 ml - uses - for the temporary relief of of itching associated with minor skin irritations and rashes due to - eczema - insect bites - poison ivy, poison oak, poison sumac - soaps and detergents cosmetics - jewelry stop use and ask a doctor if condition worsens, or if symptoms persist for more than 7 day or clear up and occur again within a few days, do not use this or any other hydrocortisone products unless you hav consulted a doctor.

VeraSeal Europäische Union - Englisch - EMA (European Medicines Agency)

veraseal

instituto grifols, s.a. - human fibrinogen, human thrombin - hemostasis, surgical - antihemorrhagics - supportive treatment in adults where standard surgical techniques are insufficient:for improvement of haemostasisas suture support in vascular surgery

LISINOPRIL AND HYDROCHLOROTHIAZIDE tablet Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

lisinopril and hydrochlorothiazide tablet

international laboratories, llc - lisinopril (unii: e7199s1ywr) (lisinopril anhydrous - unii:7q3p4bs2fd), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - lisinopril 10 mg - lisinopril and hydrochlorothiazide tablets usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a

LISINOPRIL AND HYDROCHLOROTHIAZIDE tablet Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

lisinopril and hydrochlorothiazide tablet

international laboratories, llc - lisinopril (unii: e7199s1ywr) (lisinopril anhydrous - unii:7q3p4bs2fd), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - lisinopril and hydrochlorothiazide tablets usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a

BUPROPION HYDROCHLORIDE- bupropion hydrochloride tablet, film coated, extended release Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

bupropion hydrochloride- bupropion hydrochloride tablet, film coated, extended release

mylan institutional inc. - bupropion hydrochloride (unii: zg7e5poy8o) (bupropion - unii:01zg3tpx31) - bupropion hydrochloride extended-release tablets (xl) are indicated for the treatment of major depressive disorder (mdd), as defined by the diagnostic and statistical manual (dsm). the efficacy of the immediate-release formulation of bupropion was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult patients with mdd. the efficacy of the sustained-release formulation of bupropion in the maintenance treatment of mdd was established in a long-term (up to 44 weeks), placebo-controlled trial in patients who had responded to bupropion in an 8-week study of acute treatment [see clinical studies (14.1)] . bupropion hydrochloride extended-release tablets (xl) are indicated for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder (sad). the efficacy of bupropion hydrochloride extended-release tablets in the prevention of seasonal major depressive episodes was established in 3 placebo-controlled trials in a

SUNSCREEN BROAD SPECTRUM SPF 50 VITALITY INSTITUTE- zinc oxide, octinoxate cream Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

sunscreen broad spectrum spf 50 vitality institute- zinc oxide, octinoxate cream

vitality institute medical products - zinc oxide (unii: soi2loh54z) (zinc cation - unii:13s1s8sf37), octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51) - uses - helps prevent sunburn - if used as directed with other sun protection measures (see directions), decreases the risk of skin cancer and early skin aging caused by the sun. - stop use and ask a doctor if rash occurs